MTEM
Molecular Templates, Inc.
Set alert
52-week range unavailable
- YTD
- -99.91%
- 1 year
- -99.91%
- Open
- 0.0001
- Prev close
- 0.0001
- Mkt cap
- 921.74K
- Vol
- 5
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0001
- High
- 0.0001
- Forward P/E
- -0.06
- Beta
- 1.22
- Short ratio
- 0.01
- Inst. own
- 35.01%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 23, 2024
- 50-d avg
- 0.4644
- 200-d avg
- 1.27
- 1y target
- 0.00
Key statistics
- Market cap
- 921.74K
- Enterprise value
- 2.42M
- Trailing P/E
- 0.00
- Forward P/E
- -0.06
- PEG ratio
- 0.00
- Price / sales
- 0.04
- Price / book
- 0.13
- EPS (TTM)
- -3.05
- Beta
- 1.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -61.35%
- Revenue (TTM)
- 25.47M
- Revenue growth
- -91.70%
- Free cash flow
- -17.50M
- Total cash
- 9.66M
- Total debt
- 11.03M
- Return on equity
- 0.00%
- Shares outstanding
- 6.58M
- Short % of float
- 4.57%
- 50-day average
- 0.4644
- 200-day average
- 1.27
Analyst view
Consensus: none
Next earnings
Dec 23, 2024
Expected Dec 23, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 23, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -1.23 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | 0.08 | — | — |
| Mar 29, 2024 | Dec 1, 2023 | -2.10 | -0.73 | +1.37 | +65.24% |
| Nov 13, 2023 | Sep 1, 2023 | -2.70 | -0.82 | +1.88 | +69.63% |
| Aug 10, 2023 | Jun 1, 2023 | -5.25 | -3.30 | +1.95 | +37.14% |
About Molecular Templates, Inc.
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- mtem.com
News
- RapidPulse Secures Oversubscribed $48M Series B Financing to Advance Clinical Development of Next-Generation Stroke Aspiration Technology
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules
- Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
- Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements
- Why Spirit Airlines Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket
- Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update
Your note
Sign in to keep a note on MTEM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIOTECH TARGET N V | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 13, 2024 | 0 |
| LALANDE KEVIN M | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Apr 1, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bellevue Group AG | 19.44% | 1,279,820 | 179.17K | Sep 29, 2024 |
| SilverArc Capital Management, LLC | 9.48% | 623,838 | 87.34K | Sep 29, 2024 |
| BVF Inc. | 7.93% | 522,238 | 73.11K | Sep 29, 2024 |
| Bank of Montreal /CAN/ | 1.11% | 73,125 | 10.24K | Sep 29, 2024 |
| Vanguard Group Inc | 0.77% | 50,899 | 7.13K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.72% | 47,231 | 6.61K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.76% | 49,888 | 6.98K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 29,300 | 4.10K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 7,016 | 982 | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 3,964 | 554 | Oct 30, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 14 | 1 | Aug 30, 2024 |